Bioconvergence Market Report 2026

Bioconvergence Market Overview

• Bioconvergence market size has reached to $158.2 billion in 2025 • Expected to grow to $263.67 billion in 2030 at a compound annual growth rate (CAGR) of 10.8% • Growth Driver: Growing Emphasis On Personalized Medicine Fuelling The Growth Of The Market Due To Advancements In Genomic Technologies • Market Trend: Integrated Computing in Nanopore Sequencers Enhances Laboratory Sequencing Efficiency • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Bioconvergence Market?

Bioconvergence is the integration of biology with engineering, data science, and advanced technologies to drive innovation in healthcare, biotechnology, and life sciences. Its main goal is to develop smarter, more personalized, and more efficient solutions such as precision medicine, advanced diagnostics, and bioengineered products. Bioconvergence fosters the creation of faster, cheaper, and more effective novel therapies, devices, and platforms. The main components of the bioconvergence are devices, software, services and platforms. Devices are hardware or tools that interact with biological systems, often combining biology, engineering, and digital technology. It integrates various advanced technologies, including artificial intelligence, robotics, 3D printing, nanotechnology, synthetic biology, bioinformatics, and wearable devices. These technologies support diverse applications such as drug discovery, regenerative medicine, optogenetics, nanorobotics for targeted therapies, diagnostic and biosensing tools, bioelectronics, and precision medicine. The key end users of these innovations include the pharmaceutical and biotechnology sectors, contract research organizations, and others.

What Is The Bioconvergence Market Growth Forecast?

The bioconvergence market size is expected to see rapid growth in the next few years. It will grow to $263.67 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to personalized medicine acceleration, AI-enabled life sciences, bioengineering innovation, data-driven healthcare solutions, cross-industry collaborations. Major trends in the forecast period include integration of biology with engineering systems, expansion of precision medicine platforms, growing adoption of AI-driven drug discovery, increased use of bioinformatics solutions, convergence of digital and biological technologies.

What Is The Driver Of The Bioconvergence Market?

The growing emphasis on personalized medicine is expected to propel the growth of the bioconvergence market going forward. Personalized medicine is a medical approach that involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for personalized medicine is increasing due to advancements in genomic technologies, which enable precise identification of genetic variations and tailored treatments for individuals. Bioconvergence enhances personalized medicine by integrating advanced technologies with biological research, enabling more precise, individualized treatment plans tailored to a patient’s genetic and molecular profile. It improves healthcare outcomes by facilitating targeted therapies and reducing adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the growing emphasis on personalized medicine is driving the growth of the bioconvergence industry.

Key Players In The Global Bioconvergence Market

Major companies operating in the bioconvergence market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Veolia Environnement S.A, Novartis AG, Eli Lilly and Company, Amgen Inc., HDR Inc., Ginkgo Bioworks, BICO Group AB, MeMed Diagnostics Ltd., Anima Biotech, Singota Solutions LLC, SetPoint Medical Corporation, Galvani Bioelectronics, Ezassi Inc., Tissue Dynamics Ltd., Sanara Ventures Ltd., BioConvergent Health LLC, Gradiant Bioconvergence Center

Global Bioconvergence Market Trends and Insights

Major companies operating in the bioconvergence market are focusing on developing innovative products, such as integrated nanopore sequencing devices with onboard computing, to eliminate external computing dependencies, enable real-time data analysis, and streamline laboratory workflows. An integrated nanopore sequencing device with onboard computing is a self-contained benchtop system that performs DNA, RNA, and cDNA sequencing with built-in basecalling and analysis capabilities. For instance, in March 2024, Oxford Nanopore Technologies, a UK-based biotechnology company, launched the PromethION 2 Integrated (P2i) to democratize high-output nanopore sequencing for small and medium-sized research laboratories. This innovative bioconvergence tool enables on-device real-time basecalling using onboard NVIDIA Ampere architecture GPU, allowing researchers to generate up to 290 gigabases of data per flow cell, eliminate dependency on external computing infrastructure, and gain immediate biological insights through integrated MinKNOW software with plug-and-play functionality. The PromethION 2 Integrated is highly versatile, offering effective sequencing capabilities for diverse applications including whole-genome sequencing of large organisms, comprehensive metagenomic studies, and full-transcript-length RNA analysis by combining two independently addressable flow cells with integrated touchscreen control and 15 terabytes of onboard storage for improved workflow efficiency and data quality.

What Are Latest Mergers And Acquisitions In The Bioconvergence Market?

In November 2024, Quris-AI, an Israel and US-based biotechnology company, acquired Nortis (Numa Biosciences, Inc.) for an undisclosed amount. With this acquisition, Quris-AI enhances its bioconvergence portfolio by integrating Nortis's Kidney-on-Chip microphysiology systems technology, enabling earlier identification of harmful drug candidates through improved renal toxicity assessments and pharmacokinetic predictions while supporting enhanced accuracy and efficiency in preclinical and clinical drug safety predictions. Nortis is a US-based biotechnology company that involves bioconvergence.

What Defines the Bioconvergence Market?

The bioconvergence market consists of revenues earned by entities by providing services such as personalized medicine development, biomedical data analysis, bioinformatics platforms, regenerative medicine solutions, diagnostic technology integration, and smart medical device engineering. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioconvergence market also includes sales of bioprinted tissues and organs, lab-on-a-chip devices, smart implants, bioengineered materials, and integrated diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Bioconvergence Market Report 2026?

The bioconvergence market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the bioconvergence industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.